RNF213 marks a regulatory T-cell subset associated with ulcerative colitis
-
By
-
Zhangqin Li
-
Jing Wu
-
Jiayi Yang
-
Lianyu Zhou
-
Lifang Chen
-
Youxu Ren
-
Yunxing Li
-
Ruijie Ma
-
Yinglei Miao
-
Jie Jia
-
Jiarong Miao
-
July 6, 2026
-
Clinical Scorecard: RNF213 Identifies a Regulatory T-Cell Subpopulation Linked to Ulcerative Colitis
At a Glance
| Category | Detail |
|---|
| Condition | Ulcerative Colitis |
| Key Mechanisms | Ubiquitination and Treg differentiation mediated by RNF213. |
| Target Population | Patients with Ulcerative Colitis. |
| Care Setting | Clinical research and diagnostic validation. |
Key Highlights
- RNF213 identified as a key biomarker in UC-associated Tregs.
- Superior diagnostic performance of RNF213 with AUC > 0.9.
- Increased RNF213+ Tregs observed in UC patients compared to healthy controls.
- Altered ligand-receptor interactions predicted among immune cell populations.
- Potential for RNF213 to inform targeted therapies in UC.
Guideline-Based Recommendations
Diagnosis
- Use of machine learning algorithms for biomarker identification.
Management
- Consider RNF213 as a target for therapeutic strategies.
Monitoring & Follow-up
- Assess RNF213 levels in Tregs for disease activity evaluation.
Risks
- Potential for infections associated with current UC treatments.
Patient & Prescribing Data
Patients undergoing treatment for Ulcerative Colitis.
Infliximab used for induction therapy in study patients.
Clinical Best Practices
- Integrate scRNA-seq and transcriptomic data for comprehensive analysis.
- Utilize modified Mayo score and Mayo Endoscopic Subscore for disease assessment.
Related Resources & Content
